JNJ · Johnson & Johnson

Johnson & Johnson delivered strong first-quarter 2026 results with 9.9% reported sales growth to $24.1 billion, driven by robust performance across both business segments. The Innovative Medicine segment grew 11.2% to $15.4 billion, with oncology products DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE leading growth alongside immunology drug TREMFYA and neuroscience product SPRAVATO. The MedTech segment grew 7.7% to $8.6 billion, supported by cardiovascular products including electrophysiology, Abiomed, and Shockwave, as well as trauma products in orthopaedics. While GAAP net earnings declined due to special items, adjusted net earnings of $6.6 billion and adjusted EPS of $2.70 showed more stable underlying performance. Management highlighted multiple regulatory approvals during the quarter, including ICOTYDE for plaque psoriasis and VARIPULSE Pro in Europe, which CEO Joaquin Duato described as 'game-changing' advancements with potential to transform patient outcomes. The company raised its full-year 2026 guidance, now expecting reported sales of $100.8 billion at the midpoint (7.0% growth) and adjusted EPS of $11.55 at the midpoint (7.1% growth), reflecting confidence in continued momentum. Separately, the board approved a 3.1% dividend increase to $1.34 per share, marking the 64th consecutive year of dividend increases and demonstrating the company's commitment to shareholder returns. The company also announced plans for an Enterprise Business Review on December 8, 2026, suggesting ongoing strategic evaluation of its portfolio and operations.